Effect of Azithromycin on Airflow Decline-Free Survival After Allogeneic Hematopoietic Stem Cell Transplant: The ALLOZITHRO Randomized Clinical Trial.

Date publication

août 2017

Journal

JAMA

Auteurs

Membres identifiés du Cancéropôle Est :
Dr BERCEANU Ana , Pr FORNECKER Luc-Matthieu

Tous les auteurs :
Bergeron A, Chevret S, Granata A, Chevallier P, Vincent L, Huynh A, Tabrizi R, Labussiere-Wallet H, Bernard M, Chantepie S, Bay JO, Thiebaut-Bertrand A, Thepot S, Contentin N, Fornecker LM, Maillard N, Risso K, Berceanu A, Blaise D, Peffault de La Tour R, Chien JW, Coiteux V, Socié G,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/28787506

Résumé

Bronchiolitis obliterans syndrome has been associated with increased morbidity and mortality after allogeneic hematopoietic stem cell transplant (HSCT). Previous studies have suggested that azithromycin may reduce the incidence of post-lung transplant bronchiolitis obliterans syndrome.

Mots clés

Adult, Anti-Bacterial Agents, adverse effects, Azithromycin, adverse effects, Bronchiolitis Obliterans, etiology, Disease-Free Survival, Double-Blind Method, Female, Hematologic Neoplasms, mortality, Hematopoietic Stem Cell Transplantation, adverse effects, Humans, Intention to Treat Analysis, Male, Middle Aged, Recurrence, Respiratory Function Tests, Transplantation Conditioning, Transplantation, Homologous, Treatment Failure

Référence

JAMA. 2017 Aug;318(6):557-566